Zhang Xiaoyu, Jia Yulong, Chou Chenxu, Duan Xiaguang
Baotou Medical College Baotou 014040, Inner Mongolia, China.
Department of Anesthesiology, Inner Mongolia Baogang Hospital Baotou 014010, Inner Mongolia, China.
Am J Transl Res. 2025 May 15;17(5):3971-3981. doi: 10.62347/CEED1530. eCollection 2025.
This study aimed to investigate the analgesic effects of Pectoral Nerve Block Type II (PECS II) versus Rhomboid Intercostal and Subserratus Plane Block (RISS) after modified radical mastectomy (MRM) for breast cancer.
This prospective, double-blind, randomized controlled trial recruited 67 female patients undergoing unilateral MRM from December 1, 2023, to December 1, 2024 at Inner Mongolia Baogang Hospital. Patients were randomly assigned (1:1) to the PECS II group (n=30) or the RISS group (n=30). Primary outcomes included Quality of Recovery (QoR-40) scores at 6 and 24 hours and Visual Analogue Scale (VAS) pain scores in the PACU and at 2, 6, 12, 24, and 48 hours postoperatively. Secondary outcomes included sufentanil consumption via PCIA, the number of effective compressions, remifentanil use during surgery, additional analgesic administrations, sleep quality, and adverse events.
The PECS II group demonstrated significantly lower VAS scores than the RISS group at rest and during movement in the PACU and at 2, 6, 12, and 24 hours (P<0.05). The QoR-40 score at 6 hours was significantly higher in the PECS II group (P<0.0001). The remifentanil consumption, sufentanil dosage and effective compressions via PCIA during surgery were also significantly lower in the PECS II group, compared to the RISS group (P<0.0001).
PECS II block appears to be a more effective analgesic technique than RISS block for patients undergoing breast cancer surgery, providing better pain control, reducing opioid consumption, and potentially facilitating faster recovery.
本研究旨在探讨Ⅱ型胸神经阻滞(PECSⅡ)与菱形肌肋间及锯肌下平面阻滞(RISS)对乳腺癌改良根治术(MRM)后患者的镇痛效果。
本前瞻性、双盲、随机对照试验于2023年12月1日至2024年12月1日在内蒙古包钢医院招募了67例行单侧MRM的女性患者。患者被随机(1:1)分配至PECSⅡ组(n = 30)或RISS组(n = 30)。主要结局指标包括术后6小时和24小时的恢复质量(QoR - 40)评分,以及麻醉后恢复室(PACU)和术后2、6、12、24及48小时的视觉模拟评分(VAS)疼痛评分。次要结局指标包括通过患者自控静脉镇痛(PCIA)使用的舒芬太尼用量、有效按压次数、术中瑞芬太尼使用情况、额外镇痛药物使用情况、睡眠质量及不良事件。
在PACU以及术后2、6、12和24小时,PECSⅡ组在静息和活动时的VAS评分均显著低于RISS组(P < 0.05)。PECSⅡ组术后6小时的QoR - 40评分显著更高(P < 0.0001)。与RISS组相比,PECSⅡ组术中瑞芬太尼用量、舒芬太尼剂量及通过PCIA的有效按压次数也显著更低(P < 0.0001)。
对于接受乳腺癌手术的患者,PECSⅡ阻滞似乎是一种比RISS阻滞更有效的镇痛技术,能提供更好的疼痛控制,减少阿片类药物消耗,并可能促进更快恢复。